Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 9/20 | 0.50 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.33 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | USP19 | O94966 | 6/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1916466 | 1.00 | FFAR2 (0.50) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL2401786 | 0.94 | FFAR2 (0.44) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL2401784 | 0.94 | FFAR2 (0.44) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL1916391 | 0.94 | FFAR2 (0.45) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL1916386 | 0.94 | FFAR2 (0.45) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL2398713 | 0.94 | FFAR2 (0.51) | FFAR2USP19 | |
| SCHEMBL2398706 | 0.94 | FFAR2 (0.51) | FFAR2USP19 | |
| SCHEMBL2397466 | 0.93 | FFAR2 (0.44) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL2397469 | 0.93 | FFAR2 (0.44) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL2402855 | 0.92 | FFAR2 (0.47) | FFAR2BMPR1BBMPR1AACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | claimed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | claimed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | FFAR2 295/4885BMPR1B 2168/4885BMPR1A 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.